Quoin Pharmaceuticals, Ltd.
QNRX
$6.69
$0.09141.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.93M | 5.98M | 5.99M | 6.00M | 6.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.53M | 9.34M | 8.94M | 9.06M | 9.38M |
| Operating Income | -9.53M | -9.34M | -8.94M | -9.06M | -9.38M |
| Income Before Tax | -8.96M | -8.70M | -8.28M | -8.41M | -8.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.96 | -8.70 | -8.28 | -8.41 | -8.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.96M | -8.70M | -8.28M | -8.41M | -8.69M |
| EBIT | -9.53M | -9.34M | -8.94M | -9.06M | -9.38M |
| EBITDA | -9.43M | -9.24M | -8.84M | -8.96M | -9.27M |
| EPS Basic | -2.84K | -4.95K | -6.77K | -8.90K | -12.55K |
| Normalized Basic EPS | -50.66 | -88.34 | -120.86 | -158.99 | -224.13 |
| EPS Diluted | -2.84K | -4.95K | -6.77K | -8.90K | -12.55K |
| Normalized Diluted EPS | -50.66 | -88.34 | -120.86 | -158.99 | -224.13 |
| Average Basic Shares Outstanding | 535.60K | 376.90K | 260.80K | 144.70K | 102.80K |
| Average Diluted Shares Outstanding | 15.20K | 10.70K | 7.40K | 4.10K | 2.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |